Genomic Instability in Cancer II: 4N-Skewed (90°) Reductive Division via Fragile Sites to Fitness Increase for Solid and Hematological Cancer Beginnings

ISSN Print: 2151-1934
ISSN Online: 2151-1942
www.scirp.net/journal/jct
E-mail: [email protected]

Citations

"Genomic Instability in Cancer II: 4N-Skewed (90°) Reductive Division via Fragile Sites to Fitness Increase for Solid and Hematological Cancer Beginnings"
written by Kirsten H. Walen,
published by Journal of Cancer Therapy, Vol.10 No.7, 2019

has been cited by the following article(s):

[1]	Epigenetic Enabled Normal Human Cells, Lead to First Cell's Unique Division System, Driving Tumorigenesis Evolution
	Journal of Cancer Therapy, 2022

[2]	CELL CYCLE STRESS IN NORMAL HUMAN CELLS: A ROUTE TO “FIRST CELLS”(WITH/WITHOUT FITNESS GAIN) AND CANCER-LIKE CELL-SHAPE CHANGES
	2021

[3]	A Traceable Cancer Model: DNA Damage, Fragile Site-SMGs, Mitotic Slippage, 4n-Genome-Reduction to Fitness-Gained, Initiating, 2n First Cells
	2021

[4]	Near-Dead Cells to Special Tetraploidy to First Cells to Cancer Diagnostic Morphology: Unlikely Therapy-Gain from For-Profit Industrial Goliath
	2020

[1]	Amitotic Cell Division, Malignancy, and Resistance to Anticancer Agents: A Tribute to Drs. Walen and Rajaraman Cancers, 2024 DOI:10.3390/cancers16173106

[2]	Epigenetic Enabled Normal Human Cells, Lead to First Cell’s Unique Division System, Driving Tumorigenesis Evolution Journal of Cancer Therapy, 2022 DOI:10.4236/jct.2022.131004

[3]	Cell cycle stress in normal human cells: A route to “first cells” (with/without fitness gain) and cancer-like cell-shape changes Seminars in Cancer Biology, 2022 DOI:10.1016/j.semcancer.2020.12.023

[4]	A Traceable Cancer Model: DNA Damage, Fragile Site-SMGs, Mitotic Slippage, 4n-Genome-Reduction to Fitness-Gained, Initiating, 2n First Cells Journal of Cancer Therapy, 2021 DOI:10.4236/jct.2021.126033

[5]	Near-Dead Cells to Special Tetraploidy to First Cells to Cancer Diagnostic Morphology: Unlikely Therapy-Gain from For-Profit Industrial Goliath Journal of Cancer Therapy, 2020 DOI:10.4236/jct.2020.117036